ArticleIranian journal of pharmaceutical research : IJPR2018
Molecular and Biochemical Evidences for Beneficial Effects of Zinc Oxide Nanoparticles in Modulation of Chlorpyrifos Toxicity in Human Lymphocytes.
Article in Iranian journal of pharmaceutical research : IJPR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 17 citations in OpenAlex.
- Zinc nanoparticles mitigate azoxystrobin and its nanoencapsulation-induced hepatic and renal toxicity in rats.Redox report : communications in free radical research · 2025Article
- Nanoparticle-enhanced mesalazine therapy for inflammatory bowel disease.Pharmaceutical science advances · 2023Review
- ZnO nanoparticles alter redox metabolism of Limnoperna fortunei.Environmental science and pollution research international · 2021Article
- Evidence-based traditional Siddha formulations for prophylaxis and management of respiratory symptoms in COVID-19 pandemic-a review.Biocatalysis and agricultural biotechnology · 2021Review
- Impact of Acrylamide on Cellular Senescence Response and Cell Cycle Distribution via an In-vitro Study.Iranian journal of pharmaceutical research : IJPR · 2021Article
- A Randomized Clinical Trial of Elemental Zinc Add-on Therapy on Clinical Outcomes of Patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP).Iranian journal of pharmaceutical research : IJPR · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chlorpyrifos (CP), an acetylcholinesterase (AChE) inhibitor, is used throughout the world as an insecticide in agriculture and an eradicating agent for termites around homes. In the present study, we examined the protective role of zinc oxide nanoparticles (ZnO NPs) in human CP-treated lymphocytes. Lymphocytes isolated by Ficoll and exposed to 75 µg/mL CP either alone or in combination with logarithmic doses of ZnO NPs (0/1, 1, 10, 100 µg/mL). After a 3-day incubation period, the viability and oxidative stress markers were determined. Then, the levels of tumor necrosis factor-α (TNF-α), as an inflammatory index along with AChE activity and cell death were evaluated. Our results showed that incubation with CP significantly increases the percent of cell death, activities of caspase-3 and -9, level of TNF-α and also promotes the levels of biomarkers which play important role in oxidative stress. On the other hand, the activity of AChE and levels of the total antioxidant power (TAP) decreased in CP-treated lymphocytes. In contrast, lymphocytes treated with different concentrations of ZnO NPs showed a significant decrease in the percent of mortality as well as the levels of TNF-α, as compared with CP-treated lymphocytes. Besides, ZnO NPs increased the levels of AChE and TAP at 1 µg/mL. In conclusion, the results indicate the protective effects of ZnO NPs in the prevention of cytotoxic activity of CP in the lymphocytes.
Indexed as
Identifiers
30127816PMC6094429W2801351304What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.